Parkinson Hastalığında Nöroinflamasyonun Rolü

Year 2019, Volume: 26 Issue: 3, 348 - 352, 01.09.2019

Elif Taşdemir

https://doi.org/10.17343/sdutfd.447542

Cited By: 1

Abstract

Parkinson Hastalığı (PH), 65 yaş üzeri
kişilerde en sık görülen ikinci nörodejeneratif bozukluktur (1). Bu hastalık,
substantia nigra pars compacta’daki dopaminerjik nöronların progresif kaybı (2-4),
striatal dopamin seviyesinde azalma ve dopaminerjik liflerin kaybıyla
karakterizedir (5). PH’ndaki nöron dejenerasyon sürecinde; oksidatif stresin, aktive
edilmiş mikroglia hücrelerinin ve nöroinflamasyonun olduğu bilinmektedir (6).
PH, yoğun araştırma konusu olmasına rağmen hastalığın patogenezinde yatan
mekanizmalar tam olarak anlaşılamamıştır (7-8). Dolayısıyla, bu süreci tamamen
önleyen bir tedavi de bulunamamıştır. Bu derlemede, PH patogenezinde yer alan
nöroinflamasyon süreçleri incelenmiştir.

Keywords

Parkinson hastalığı, nöroinflamasyon, mikroglia

References

• 1. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism & related disorders 2012;18(1):207-9.
• 2. Episcopo FL, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Current aging science 2013;6(1):45-55.
• 3. Hernandes MS, Santos GD, Cafe-Mendes CC, Lima LS, Scavone C, Munhoz CD, et al. Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration. PloS one 2013;8(9):e75532.
• 4. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Act Neuropathol 2014;128(6):805-20.
• 5. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318(1):215-24.
• 6. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism & related disorders 2012;18(1):210-2.
• 7. Chao Y, Wong SC, Tan EK. Evidence of inflammatory system involvement in Parkinson's disease. BioMed research international 2014;2014:308654.
• 8. Jackson-Lewis V, Smeyne RJ. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotoxicity research 2005;7(3):193-202.
• 9. Nolan YM, Sullivan AM, Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends in molecular medicine 2013;19(3):187-96.
• 10. Şentürk E, Esen F. Sepsiste İmmunoglobülin Tedavisi ile Kompleman İnhibisyonu ve Nöroproteksiyon. Türk Anesteziyoloji Reanimasyon Dergisi 2012;40(4):184-92.
• 11. Laveti D, Kumar M, Hemalatha R, Sistla R, Naidu VG, Talla V, et al. Anti-inflammatory treatments for chronic diseases: a review. Inflammation & allergy drug targets 2013;12(5):349-61.
• 12. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends in pharmacological sciences 2003;24(8):395-401.
• 13. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, et al. Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clinical neuroscience research 2006;6(5):261-81.
• 14. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Current pharmaceutical design 2007;13(18):1925-8.
• 15. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009;8(4):382-97.
• 16. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 2010;117(8):971-9.
• 17. Duke DC, Moran LB, Pearce RK, Graeber MB. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007;8(2):83-94.
• 18. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007;64(11):1403-18.
• 19. Zaminelli T, Gradowski RW, Bassani TB, Barbiero JK, Santiago RM, Maria-Ferreira D, et al. Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson's disease. Neurotoxicity research 2014;26(4):351-62.
• 20. Taylor JM, Main BS, Crack PJ. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem Int 2013;62(5):803-19.
• 21. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010;185(2):1230-7.
• 22. Xing B, Liu M, Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 2007;192(1-2):89-98.
• 23. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5(12):1403-9.
• 24. Yang X, Lou Y, Liu G, Wang X, Qian Y, Ding J, et al. Microglia P2Y6 receptor is related to Parkinson’s disease through neuroinflammatory process. Journal of neuroinflammation 2017;14(1):38.
• 25. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-8.
• 26. Stojkovska I, Wagner BM, Morrison ME. Parkinson's disease and enhanced inflammatory response. Experimental biology and medicine 2015;240(11):1387-95.
• 27. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB reports 2010;43(4):225-32.
• 28. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38(8):1285-91.
• 29. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66:24-36.
• 30. Ramsey CP, Tansey MG. A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Experimental neurology 2014;256:126-32.
• 31. Tiwari PC, Pal R. The potential role of neurıinflammation and transcription factors in Parkinson disease. Dialogues in clinical neuroscience 2017;19(1):71-80.
• 32. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Current pharmaceutical design 2005;11(8):999-1016.
• 33. Rajasekar N, Dwivedi S, Nath C, Hanif K, Shukla R. Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. Neuropharmacology 2014;86:337-52.
• 34. Joe EH, Choi DJ, An J, Eun JH, Jou I, Park S. Astrocytes, Microglia, and Parkinson’s Disease. Experimental neurobiology 2018;27(2):77-87.
• 35. Lee E, Park HR, Ji ST, Lee Y, Lee J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-kappaB, ERK, and JNK. J Neurosci Res 2014;92(1):130-9.
• 36. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Movement disorders: official journal of the movement disorder society 2011;26(1):6-17.